The weight loss medication Wegovy is now available for purchase in the United Kingdom. The prescription-only drug has been approved for individuals with obesity or those who are overweight with at least one weight-related condition.
Wegovy, manufactured by Novo Nordisk, contains the active ingredient semaglutide, which is also used in a lower dose for managing type 2 diabetes under the brand name Ozempic. Semaglutide mimics a hormone called glucagon-like peptide-1 (GLP-1), which helps to regulate appetite by making people feel fuller for longer.
Clinical trials have demonstrated Wegovy's effectiveness in supporting significant weight loss when used in conjunction with a reduced-calorie diet and increased physical activity. Patients prescribed Wegovy can expect to receive guidance on diet and exercise from healthcare professionals as part of the treatment plan.
Availability in the UK marks a significant step for the drug's rollout in Europe. Healthcare providers will be responsible for prescribing Wegovy based on established clinical guidelines and patient suitability. The drug's launch aims to provide a new medical option for managing obesity, a complex health issue associated with numerous comorbidities.